Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma

Fabio Fulfaro, Lorena Incorvaia, Giuseppe Badalamenti, Giuseppe Bronte, Gaetano Leto, Lorena Incorvaia, Giuseppe Badalamenti, Salvatore Provenzano, Giuseppa Maltese, Giuseppe Badalamenti, Fabio Fulfaro, Giuseppe Bronte, Giuseppa Maltese, Salvatore Provenzano

Risultato della ricerca: Articlepeer review

5 Citazioni (Scopus)

Abstract

Background: Neutropenia and its complicationsrepresent one of the principal dose-limiting toxicity issues inchemotherapeutic regimens for soft tissue sarcoma.Prophylactic granulocyte colony-stimulating factor (G-CSF)reduces the risk of febrile neutropenia (FN). The correcttiming of G-CSF administration should be considered in orderto optimize the prophylactic treatment. Patients and Methods:Patients (≥18 years old) affected by soft tissue sarcoma andtreated with epirubicin and ifosfamide, underwent prophylactictreatment with G-CSF (lenograstim at 263 μg) from day 5 today 9. The proportion of patients experiencing FN and G4neutropenia was considered. Results: A total of 36 patientsreceiving three cycles of chemotherapy with epirubicin plusifosfamide were treated. None developed FN; G4 neutropeniawas reported in 17% of patients. No treatment delay or dosereduction was required, no antibiotic therapy wasadministered and no hospitalization occurred. Conclusion:Five-day lenograstim treatment is efficient as prophylaxis ofFN for soft tissue sarcoma chemotherapy regimens and allowsmaintenance of chemotherapy dose intensity.
Lingua originaleEnglish
pagine (da-a)679-684
Numero di pagine6
RivistaAnticancer Research
Volume33
Stato di pubblicazionePublished - 2013

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Entra nei temi di ricerca di 'Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma'. Insieme formano una fingerprint unica.

Cita questo